世界のリキッドバイオプシー市場:2027 年までの予測

出版:Daedal Research (デダルリサーチ) 出版年月:2022年11月

世界のリキッドバイオプシー市場:製品とサービス(キットと試薬、プラットフォームと機器、サービス)、血中循環型バイオマーカー(循環腫瘍細胞、CT-DNA、細胞外小胞など)、エンドユーザー(病院と研究所、政府、学術研究センター)、用途 (がん、非がん)、地域規模別分析と動向 – 2027 年までの予測
Global Liquid Biopsy Market: Analysis By Product & Services (Kits & Reagents, Platforms & Instruments and Services), By Circulating Biomarker (Circulating Tumor Cell, CT-DNA, Extracellular Vesicles, and Others), By End-User (Hospitals & Laboratories, and Government & Academic Research Centers), By Application (Cancer, and Non Cancer) By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027

ページ数 155
価格
シングルユーザライセンス USD 2,250
2-5ユーザライセンス USD 3,250
エンタープライズライセンス USD 4,250
種別 英文調査報告書

レポート目次  お問合せ・ご注文  価格・納期について

無料サンプル

The global liquid biopsy market in 2021 stood at US$1.28 billion, and is likely to reach US$3.93 billion by 2027. A liquid biopsy involves testing a sample of blood to see whether there are any cancer cells from a tumor that are circulating there or if there are any DNA fragments from tumor cells that are there. A liquid biopsy may be used to aid in the early detection of cancer.

The liquid biopsy has recently been driven by the rising incidence of cancer and the rising preference for fast, minimally invasive diagnostic testing. The liquid biopsy test is performed either on DNA isolated from tumor cells or on a blood sample to detect cancer cells existing in the blood stream. The government takes a number of steps to promote early cancer identification. The global liquid biopsy market is projected to grow at a CAGR of 20.4% during the forecast period of 2022-2027.

Market Segmentation Analysis:

By Product & Services: The market report has segmented the global liquid biopsy market into three segments on the basis of product & services: kits & reagents, platforms & instruments and services. The kits & reagents segment is the largest segment in 2021, owing to the availability of a wide range of reagents and kits, easy access to a wide range of assays, and the rising prevalence of cancer.

By Circulating Biomarker: Based on the circulating biomarker, the global liquid biopsy market has been divided into four segments: Circulating Tumor Cell, CT-DNA, Extracellular Vesicles, and Others. The CT-DNA is the fastest growing segment during the forecast period, owing to rapid development of next-generation sequencing (NGS) technologies in liquid biopsy advancements applied to circulating tumor DNA (ct DNA).

By End User: The global liquid biopsy market has been classified into two segments based on the end user: Hospitals & Laboratories, and Government & Academic Research Centers. The hospital & laboratory segment dominated the liquid biopsy market in 2021 attributed to wider usage of liquid biopsy tests across hospitals and laboratory settings which are the preferable healthcare facilities for patients.

By Application: On the basis of application, the market report has segmented the global liquid biopsy market into two segments: cancer, and non-cancer segments. The liquid biopsy market was driven by the cancer segment in 2021, attributable to the growing use of liquid biopsy techniques for the diagnosis of different cancer types. The market for cancer liquid biopsy has been further segmented based on the cancer type: lung cancer, colorectal cancer, prostate cancer, liver cancer, breast cancer, and others. The market for cancer liquid biopsy was dominated by the lung cancer segment in 2021 owing to this type of liquid biopsy has developed into a potential tool for early detection of lung cancer and disease monitoring to help further with management decisions in selected patients.

By Region: According to this report, the global liquid biopsy market can be divided into four major regions: North America (the US, Canada, and Mexico), Europe (Germany, France, UK, and Rest of Europe), Asia Pacific (Japan, China, India, South Korea, and Rest of the Asia Pacific), and Rest of the world. Due to the rising use of liquid biopsy for cancer detection in the North American region, this region has led the liquid biopsy market. The US currently dominates the worldwide liquid biopsy market because of the fast-rising number of cancer cases. The American Cancer Society estimates that there will be 1.92 million new cases of cancer in the US in 2022.

During the forecasted period of 2022–2027, Europe is expected to have the liquid biopsy market’s fastest growth rate, due to the numerous start-ups and prospective businesses that are joining the market. Germany dominated the European liquid biopsy market in 2021 because of an increase in cancer cases and the existence of significant market participants there.

Global Liquid Biopsy Market Dynamics:

Growth Drivers: According to statistics from the International Agency for Research on Cancer’s GLOBOCAN 2020 estimates, there has been about 19.3 million new cases of cancer and about 10 million cancer-related deaths in the world in 2020. Since liquid biopsies have the potential to address significant issues with diagnosis, prognosis, and treatments, the rise in the number of cancer cases has been a key market driver. Further, the market is expected to grow owing to rising healthcare expenditure, rapid urbanization, growth in demand for precision medicines, myriad of applications, etc. in recent years.

Challenges: Being a relatively new field of study, liquid biopsy has not yet benefited as substantially from studies and clinical trials as tissue biopsy has. Even though the therapeutic value of liquid biopsy is generally acknowledged, it will need several years of clinical evidence before liquid biopsy is broadly accepted. As a result, the market has recently been challenged by the need for more clinical trials. Additionally, other factors like standardized pre-analytical protocol and assay development and regulatory concerns, reimbursement, etc. are other challenges to the market.

Market Trends: Artificial intelligence is a simulation of human intelligence processes by machines. Machine learning algorithms have been extensively used to help with disease diagnosis and prognosis. These methods are being used by an increasing number of studies to identify patterns in circulating biomarkers for a variety of conditions, such as diabetes, cancer and dengue fever. Therefore, involvement of artificial intelligence in liquid biopsy is likely to upgrow the overall market, in coming years. More trends in the market are believed to grow the liquid biopsy market during the forecasted period, which may include integration of photonic technology, new in vitro fertilization technique for embryos testing, etc.

Impact Analysis of COVID-19 and Way Forward:

Governments around the world have implemented a variety of regulations and lockdowns as a result of the rise in COVID-19 cases, which has had an impact on the market growth early in the projected year. Early detection programs have been put on hold as a result. An increase in cancer mortality and morbidity is estimated in 2020 as a result of a decline in cancer screenings, visits, therapies, and operations, with differences by cancer type and service location internationally. The pandemic has also affected the logistics and supply of raw materials and components for cancer diagnostic tests as well as other crucial supplies needed to produce liquid biopsy. However, the market is likely to regain its demand owing to the assistance it provides in determining the line of treatment for cancer patients.

Competitive Landscape and Recent Developments:

Due to the existence of numerous manufacturing firms in the country, the global liquid biopsy market is highly fragmented. By investing in R&D, incorporating cutting-edge technology into their products, and providing improved products for customers, market leaders maintain their dominance. There are other strategies used, such as strategic alliances, agreements, mergers, and partnerships.

Further, key players in the liquid biopsy market are:

Guardant Health
Angle PLC
Qiagen N.V.
Thermo Fisher Scientific Inc.
Bio-rad Laboratories, Inc.
Roche Holdings AG
Johnson & Johnson Ltd.
Illumina Inc.
MDxHealth SA
Myriad Genetics, Inc.
Biocept Inc.
Mesa Laboratories Inc.
Bio-Techne Corporation

By diversifying their cancer diagnostics offerings, market participants are fostering market expansion and boosting demand for their proprietary liquid biopsy solutions. Companies are rapidly adjusting to changing market dynamics and concentrating primarily on new product introductions in order to meet the rising demand for liquid biopsy services, to boost sales, and to gain an advantage over competitors.

Leading market companies employ a variety of growth methods to gain a strong foothold in the liquid biopsy market, including strategic partnerships, collaborations, and product developments. For example: In June 2021, Biocept Inc., collaborated with Quest Diagnostics, a New Jersey-based clinical laboratory, to offer laboratory services to Quest patients for its Target Selector NGS-based liquid biopsy lung cancer panel. In February 2021, Menarini Silicon Biosystems, a developer of liquid biopsy and single-cell technologies, launched its innovative CellMag product line for staining and detection of rare circulating tumor cells (CTCs). In April 2021, Bio-Techne Company completed the acquisition of Asuragen, Inc. In February 2021, Guardant Health Company announced the availability of Guardant Reveal, the first blood-only liquid biopsy test for detecting residual and recurrent illness from a simple blood draw. The first-of-its-kind commercial test enhances the management of early-stage colorectal cancer (CRC) patients by detecting circulating tumor DNA (ctDNA) in blood after surgery to recognize patients with residual disorder who may help most from adjuvant therapy.


目次

1. Executive Summary

2. Introduction

2.1 Liquid Biopsy: An Overview
2.1.1 Definition of Liquid Biopsy
2.1.2 Application of Liquid Biopsy

2.2 Liquid Biopsy Segmentation: An Overview
2.2.1 Liquid Biopsy Segmentation
2.2.2 Cancer Liquid Biopsy Segmentation

3. Global Market Analysis

3.1 Global Liquid Biopsy Market: An Analysis

3.1.1 Global Liquid Biopsy Market: An Overview
3.1.2 Global Liquid Biopsy Market by Value
3.1.3 Global Liquid Biopsy Market by Product & Service (Kits & Reagents, Platforms & Instruments and Services)
3.1.4 Global Liquid Biopsy Market by Circulating Biomarker (Circulating Tumor Cell, CT-DNA, Extracellular Vesicles, and Others)
3.1.5 Global Liquid Biopsy Market by End-User (Hospitals & Laboratories, and Government & Academic Research Centers)
3.1.6 Global Liquid Biopsy Market by Application (Cancer, and Non-Cancer)
3.1.7 Global Liquid Biopsy Market by Region (North America, Europe, Asia Pacific, and Rest of the world)

3.2 Global Liquid Biopsy Market: Product & Service Analysis

3.2.1 Global Liquid Biopsy Market by Product & Service: An Overview
3.2.2 Global Kits & Reagents Liquid Biopsy Market by Value
3.2.3 Global Platforms & Instruments Liquid Biopsy Market by Value
3.2.4 Global Services Liquid Biopsy Market by Value

3.3 Global Liquid Biopsy Market: Circulating Biomarker Analysis

3.3.1 Global Liquid Biopsy Market by Circulating Biomarker: An Overview
3.3.2 Global Circulating Tumor Cell Liquid Biopsy Market by Value
3.3.3 Global CT-DNA Liquid Biopsy Market by Value
3.3.4 Global Extracellular Vesicles Liquid Biopsy Market by Value
3.3.5 Global Others Liquid Biopsy Market by Value

3.4 Global Liquid Biopsy Market: End User Analysis

3.4.1 Global Liquid Biopsy Market by End User: An Overview
3.4.2 Global Hospitals & Laboratories Liquid Biopsy Market by Value
3.4.3 Global Government & Academic Research Centers Liquid Biopsy Market by Value

3.5 Global Liquid Biopsy Market: Application Analysis

3.5.1 Global Liquid Biopsy Market by Application: An Overview
3.5.2 Global Cancer Liquid Biopsy Market by Value
3.5.3 Global Cancer Liquid Biopsy Market by Cancer Type
3.5.4 Global Cancer Liquid Biopsy Segment Market by Value
3.5.5 Global Non-Cancer Liquid Biopsy Market by Value

4. Regional Market Analysis

4.1 North America Liquid Biopsy Market: An Analysis

4.1.1 North America Liquid Biopsy Market: An Overview
4.1.2 North America Liquid Biopsy Market by Value
4.1.3 North America Liquid Biopsy Market by Region (the US, Canada, and Mexico)
4.1.4 The US Liquid Biopsy Market by Value
4.1.5 Canada Liquid Biopsy Market by Value
4.1.6 Mexico Liquid Biopsy Market by Value

4.2 Europe Liquid Biopsy Market: An Analysis

4.2.1 Europe Liquid Biopsy Market: An Overview
4.2.2 Europe Liquid Biopsy Market by Value
4.2.3 Europe Liquid Biopsy Market by Region (Germany, France, UK, and Rest of Europe)
4.2.4 Germany Liquid Biopsy Market by Value
4.2.5 France Liquid Biopsy Market by Value
4.2.6 UK Liquid Biopsy Market by Value
4.2.7 Rest of Europe Liquid Biopsy Market by Value

4.3 Asia Pacific Liquid Biopsy Market: An Analysis

4.3.1 Asia Pacific Liquid Biopsy Market: An Overview
4.3.2 Asia Pacific Liquid Biopsy Market by Value
4.3.3 Asia Pacific Liquid Biopsy Market by Region (Japan, China, India, South Korea, and Rest of the Asia Pacific)
4.3.4 Japan Liquid Biopsy Market by Value
4.3.5 China Liquid Biopsy Market by Value
4.3.6 India Liquid Biopsy Market by Value
4.3.7 South Korea Liquid Biopsy Market by Value
4.3.8 Rest of Asia Pacific Liquid Biopsy Market by Value

4.4 Rest of the World Liquid Biopsy Market: An Analysis

4.4.1 Rest of the World Liquid Biopsy Market: An Overview
4.4.2 Rest of the World Liquid Biopsy Market by Value

5. Impact of COVID

5.1 Impact of COVID-19 on Global Liquid Biopsy Market
5.2 post-COVID-19 Impact on Global Liquid Biopsy Market

6. Market Dynamics

6.1 Growth Driver
6.1.1 Rising Healthcare Expenditure
6.1.2 Increasing in Global Urbanization
6.1.3 Surging Incidence of Cancer Cases
6.1.4 Growth In Demand For Precision Medicines
6.1.5 Myriad of Applications

6.2 Challenges
6.2.1 Need For More Clinical Trials
6.2.2 Standardized Pre-analytical Protocol And Assay Development And Regulatory Concerns

6.3 Market Trends
6.3.1 Involvement of Artificial Intelligence
6.3.2 Integration of Photonic Technology
6.3.3 New In Vitro Fertilization Technique For Embryos Testing

7. Competitive Landscape

7.1 Global Liquid Biopsy Market Players: Product Comparison
7.2 Global Liquid Biopsy Market Players: Product Trail Comparison

8. Company Profiles

8.1 Guardant Health
8.1.1 Business Overview
8.1.2 Business Strategy

8.2 Angle PLC
8.2.1 Business Overview
8.2.2 Revenue by Product & Service
8.2.3 Business Strategy

8.3 Qiagen N.V.
8.3.1 Business Overview
8.3.2 Revenue by Product Category
8.3.2 Business Strategy

8.4 Thermo Fisher Scientific Inc.
8.4.1 Business Overview
8.4.2 Operating Segment
8.4.3 Business Strategy

8.5 Bio-rad Laboratories, Inc.
8.5.1 Business Overview
8.5.2 Operating Segment
8.5.3 Business Strategy

8.6 Roche Holdings AG
8.6.1 Business Overview
8.6.2 Operating Segment
8.6.3 Business Strategy

8.7 Johnson & Johnson Ltd.
8.7.1 Business Overview
8.7.2 Operating Segment
8.7.3 Business Strategy

8.8 Illumina Inc.
8.8.1 Business Overview
8.8.2 Operating Segment
8.8.3 Business Strategy

8.9 MDxHealth SA
8.9.1 Business Overview
8.9.2 Operating Segment
8.9.3 Business Strategy

8.10 Myriad Genetics, Inc.
8.10.1 Business Overview
8.10.2 Business Strategy

8.11 Biocept Inc.
8.11.1 Business Overview
8.11.2 Business Strategy

8.12 Mesa Laboratories Inc.
8.12.1 Business Overview
8.12.2 Operating Segment
8.12.3 Business Strategy

8.13 Bio-Techne Corporation
8.13.1 Business Overview
8.13.2 Operating Segment
8.13.3 Business Strategy

List of Figures

Figure 1: Application of Liquid Biopsy
Figure 2: Liquid Biopsy Segmentation
Figure 3: Cancer Liquid Biopsy Segmentation
Figure 4: Global Liquid Biopsy Market by Value; 2017-2021 (US$ Billion)
Figure 5: Global Liquid Biopsy Market by Value; 2022-2027 (US$ Billion)
Figure 6: Global Liquid Biopsy Market by Product & Service; 2021 (Percentage, %)
Figure 7: Global Liquid Biopsy Market by Circulating Biomarker; 2021 (Percentage, %)
Figure 8: Global Liquid Biopsy Market by End-User; 2021 (Percentage, %)
Figure 9: Global Liquid Biopsy Market by Application; 2021 (Percentage, %)
Figure 10: Global Liquid Biopsy Market by Region; 2021 (Percentage, %)
Figure 11: Global Kits & Reagents Liquid Biopsy Market by Value, 2017-2021 (US$ Million)
Figure 12: Global Kits & Reagents Liquid Biopsy Market by Value, 2022-2027 (US$ Billion)
Figure 13: Global Platforms & Instruments Liquid Biopsy Market by Value, 2017-2021 (US$ Million)
Figure 14: Global Platforms & Instruments Liquid Biopsy Market by Value, 2022-2027 (US$ Million)
Figure 15: Global Services Liquid Biopsy Market by Value, 2017-2021 (US$ Million)
Figure 16: Global Service Liquid Biopsy Market by Value, 2022-2027 (US$ Million)
Figure 17: Global Circulating Tumor Cell Liquid Biopsy Market by Value, 2017-2021 (US$ Million)
Figure 18: Global Circulating Tumor Cell Liquid Biopsy Market by Value, 2022-2027 (US$ Billion)
Figure 19: Global CT-DNA Liquid Biopsy Market by Value, 2017-2021 (US$ Million)
Figure 20: Global CT-DNA Liquid Biopsy Market by Value, 2022-2027 (US$ Million)
Figure 21: Global Extracellular Vesicles Liquid Biopsy Market by Value, 2017-2021 (US$ Million)
Figure 22: Global Extracellular Vesicles Liquid Biopsy Market by Value, 2022-2027 (US$ Million)
Figure 23: Global Others Liquid Biopsy Market by Value, 2017-2021 (US$ Million)
Figure 24: Global Others Liquid Biopsy Market by Value, 2022-2027 (US$ Million)
Figure 25: Global Hospitals & Laboratories Liquid Biopsy Market by Value, 2017-2021 (US$ Million)
Figure 26: Global Hospitals & Laboratories Liquid Biopsy Market by Value, 2022-2027 (US$ Billion)
Figure 27: Global Government & Academic Research Centers Liquid Biopsy Market by Value, 2017-2021 (US$ Million)
Figure 28: Global Government & Academic Research Centers Liquid Biopsy Market by Value, 2022-2027 (US$ Million)
Figure 29: Global Cancer Liquid Biopsy Market by Value, 2017-2021 (US$ Million)
Figure 30: Global Cancer Liquid Biopsy Market by Value, 2022-2027 (US$ Billion)
Figure 31: Global Cancer Liquid Biopsy Market by Cancer Type; 2021 (Percentage, %)
Figure 32: Global Cancer Liquid Biopsy Segment Market by Value, 2017-2021 (US$ Million)
Figure 33: Global Cancer Liquid Biopsy Segment Market by Value, 2022-2027 (US$ Billion)
Figure 34: Global Non-Cancer Liquid Biopsy Market by Value, 2017-2021 (US$ Million)
Figure 35: Global Non- Cancer Liquid Biopsy Market by Value, 2022-2027 (US$ Million)
Figure 36: North America Liquid Biopsy Market by Value; 2017-2021 (US$ Million)
Figure 37: North America Liquid Biopsy Market by Value; 2022-2027 (US$ Million)
Figure 38: North America Liquid Biopsy Market by Region; 2021 (Percentage, %)
Figure 39: The US Liquid Biopsy Market by Value, 2017-2021 (US$ Million)
Figure 40: The US Liquid Biopsy Market by Value, 2022-2027 (US$ Million)
Figure 41: Canada Liquid Biopsy Market by Value, 2017-2021 (US$ Million)
Figure 42: Canada Liquid Biopsy Market by Value, 2022-2027 (US$ Million)
Figure 43: Mexico Liquid Biopsy Market by Value, 2017-2021 (US$ Million)
Figure 44: Mexico Liquid Biopsy Market by Value, 2022-2027 (US$ Million)
Figure 45: Europe Liquid Biopsy Market by Value; 2017-2021 (US$ Million)
Figure 46: Europe Liquid Biopsy Market by Value; 2022-2027 (US$ Million)
Figure 47: Europe Liquid Biopsy Market by Region; 2021 (Percentage, %)
Figure 48: Germany Liquid Biopsy Market by Value; 2017-2021 (US$ Million)
Figure 49: Germany Liquid Biopsy Market by Value; 2022-2027 (US$ Million)
Figure 50: France Liquid Biopsy Market by Value; 2017-2021 (US$ Million)
Figure 51: France Liquid Biopsy Market by Value; 2022-2027 (US$ Million)
Figure 52: UK Liquid Biopsy Market by Value; 2017-2021 (US$ Million)
Figure 53: UK Liquid Biopsy Market by Value; 2022-2027 (US$ Million)
Figure 54: Rest of Europe Liquid Biopsy Market by Value; 2017-2021 (US$ Million)
Figure 55: Rest of Europe Liquid Biopsy Market by Value; 2022-2027 (US$ Million)
Figure 56: Asia Pacific Liquid Biopsy Market by Value; 2017-2021 (US$ Million)
Figure 57: Asia Pacific Liquid Biopsy Market by Value; 2022-2027 (US$ Million)
Figure 58: Asia Pacific Liquid Biopsy Market by Region; 2021 (Percentage, %)
Figure 59: Japan Liquid Biopsy Market by Value; 2017-2021 (US$ Million)
Figure 60: Japan Liquid Biopsy Market by Value; 2022-2027 (US$ Million)
Figure 61: China Liquid Biopsy Market by Value; 2017-2021 (US$ Million)
Figure 62: China Liquid Biopsy Market by Value; 2022-2027 (US$ Million)
Figure 63: India Liquid Biopsy Market by Value; 2017-2021 (US$ Million)
Figure 64: India Liquid Biopsy Market by Value; 2022-2027 (US$ Million)
Figure 65: South Korea Liquid Biopsy Market by Value; 2017-2021 (US$ Million)
Figure 66: South Korea Liquid Biopsy Market by Value; 2022-2027 (US$ Million)
Figure 67: Rest of Asia Pacific Liquid Biopsy Market by Value; 2017-2021 (US$ Million)
Figure 68: Rest of Asia Pacific Liquid Biopsy Market by Value; 2022-2027 (US$ Million)
Figure 69: Rest of the World Liquid Biopsy Market by Value; 2017-2021 (US$ Million)
Figure 70: Rest of the World Liquid Biopsy Market by Value; 2022-2027 (US$ Million)
Figure 71: Global Health Spending Per Capita; 2017-2021 (US$ Million)
Figure 72: Global Urban Population; 2017-2021 (Percentage, %)
Figure 73: The US Estimated Number of New Cancer Cases; 2017-2022 (Million)
Figure 74: Global Artificial Intelligence (AI) Market Revenues; 2020-2023 (US$ Billion)
Figure 75: Angle PLC Revenue by Product & Service; 2021 (Percentage, %)
Figure 76: Qiagen N.V. Revenue by Product Category; 2021 (Percentage, %)
Figure 77: Thermo Fisher Scientific Inc. Revenues by Segment; 2021 (Percentage, %)
Figure 78: Bio-rad Laboratories, Inc. Net Sales by Segment; 2021 (Percentage, %)
Figure 79: Roche Holdings AG Revenues by Operating Segment; 2021 (Percentage, %)
Figure 80: Johnson & Johnson Ltd. Sales by Segments; 2021 (Percentage, %)
Figure 81: Illumina Inc. Revenues by Segment; 2022 (Percentage, %)
Figure 82: MDxHealth SA Revenues by Segment; 2021 (Percentage, %)
Figure 83: Mesa Laboratories Inc. Revenues by Segment; 2022 (Percentage, %)
Figure 84: Bio-Techne Corporation Net Sales by Segment; 2022 (Percentage, %)
Table 1: Global Liquid Biopsy Market Players: Product Comparison
Table 2: Global Liquid Biopsy Market Players: Product Trail Comparison


    お問合せフォーム

    • レポートのタイトルは自動で入ります。

    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com